Loading people...
Laura Deming is the Co-founder and Chief Executive Officer of Until, a biotechnology company developing reversible cryopreservation technologies for human tissue and organs. She began her scientific career in genetics as a child prodigy, joining the laboratory of prominent aging researcher Cynthia Kenyon at the age of 11 to study the fundamental biological mechanisms of aging. At age 17, Deming transitioned into biotechnology investment by launching The Longevity Fund, establishing one of the first venture capital firms dedicated exclusively to extending human healthspan. Through this specialized investment vehicle, she provided critical early-stage capital to numerous startups focused on treating age-related diseases and advancing biological preservation techniques. Her current operational focus centers entirely on building Until, where she leads engineering efforts to create advanced vitrification systems that could eventually enable long-term organ storage and medical hibernation.
Laura Deming stands as a prominent figure in the world of venture capital, particularly within the burgeoning field of longevity research and investment. As a Partner at The Longevity Fund, she plays a pivotal role in identifying and nurturing companies poised to revolutionize human health and extend healthy lifespan. Her work at the fund involves leading investments in cutting-edge biotechnology, pharmaceutical development, and diagnostic tools that address the fundamental mechanisms of aging.
Deming's journey into this specialized domain began remarkably early. A true prodigy, she gained admission to the Massachusetts Institute of Technology (MIT) at the tender age of 14, where her fascination with the science of aging deepened. This early immersion in scientific inquiry laid the groundwork for her future endeavors, positioning her as a visionary in a field that many were only beginning to consider. Her unique background provides her with a profound understanding of the scientific complexities involved in extending lifespan, allowing her to evaluate potential investments with a critical and informed perspective.
At The Longevity Fund, Laura Deming's investment focus is broad yet deeply specialized. She seeks out companies developing therapies that target age-related diseases, cellular rejuvenation technologies, novel drug discovery platforms, and innovative diagnostics that can predict or mitigate the effects of aging. Her investment philosophy is rooted in the belief that scientific advancements can significantly impact the quality and duration of human life, transforming how we approach health in later years. The fund, under her guidance, aims to back ventures that are not just incrementally improving existing treatments but are fundamentally altering our understanding and control over the aging process.
While specific notable investments are often confidential in early-stage venture capital, Deming's influence is evident in the types of companies The Longevity Fund supports. These typically include firms working on areas such as senolytics (drugs that clear senescent cells), gene therapies for age-related conditions, metabolic interventions, and regenerative medicine. Her strategic insights and deep network within the scientific community have been instrumental in positioning The Longevity Fund as a leader in this high-impact sector. Laura Deming continues to be a driving force, pushing the boundaries of what is possible in the quest for a longer, healthier human existence.
Laura Deming is a Partner at The Longevity Fund, a venture capital firm focused on extending healthy human lifespan. She is known for her pioneering work in longevity investment and for starting MIT at the age of 14.
Laura Deming invests in early-stage biotechnology, pharmaceuticals, and diagnostics. Her focus areas include therapies for age-related diseases, cellular rejuvenation technologies, and other scientific advancements aimed at extending healthy human lifespan.
Laura Deming works as a Partner at The Longevity Fund, a venture capital firm dedicated to investing in companies that are developing technologies to extend healthy human lifespan.
